Navigation Links
Probiotic bacterium lessens severity of Salmonella infections by hoarding iron
Date:7/17/2013

Irvine, Calif., July 17, 2013 UC Irvine microbiologists have learned how a probiotic bacterium used to treat irritable bowel syndrome can soothe gut bacterial infections caused by Salmonella, paving the way for potential relief from foodborne illnesses that affect millions of people annually.

Manuela Raffatellu, assistant professor of microbiology & molecular genetics, and colleagues at UC Irvine and the University of Washington identified how a probiotic strain of E. coli reduces Salmonella colonization by competing with this pathogen for iron, an essential nutrient that Salmonella acquires in the gut in order to replicate at high levels.

In fact, the researchers discovered that the E. coli strain called Nissle 1917 acquires iron more efficiently than does Salmonella. As a result, Salmonella counts in the gut decrease when Nissle is administered during infection. Study results appear in today's issue of Cell Host & Microbe.

"Although we focused on Salmonella, our findings suggest that this approach can be effective against other gut bacterial pathogens that need iron to grow," said Raffatellu, who's also a member of UC Irvine's Institute for Immunology. "By understanding how these 'bad bugs' get nutrients, we can further study methods to eradicate them."

Most people infected with Salmonella develop diarrhea, fever and abdominal cramps 24 to 72 hours after infection. The illness usually lasts four to seven days, and the majority of affected individuals recover without treatment. According to the Centers for Disease Control & Prevention, about 42,000 cases of salmonellosis are reported annually in the U.S. Because many milder cases are not diagnosed or reported, the actual number of infections is estimated to be between 1 million and 4 million per year.

For nearly a century, the E. coli Nissle 1917 strain has been administered to patients with a variety of bowel disorders, but little has been known about how this probiotic bacterium works. Nissle 1917 is a key ingredient in a German probiotic product currently unavailable in the U.S. market.


'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Related biology news :

1. Study shows probiotic Lactobacillus reuteri NCIMB 30242 significantly increased vitamin D levels
2. Study finds taking probiotics has benefits for patients in hospitals
3. Probiotics found to reduce hepatic encephalopathy
4. Study: Probiotics reduce stress-induced intestinal flare-ups
5. New study shows probiotics help fish grow up faster and healthier
6. Behind closed doors: Researchers show how probiotics boost plant immunity
7. By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates
8. Invisible helpers: How probiotic bacteria protect against inflammatory bowel diseases
9. Scientists discover ethnic differences in immune response to TB bacterium
10. Bacterium counteracts coffee ring effect
11. Scientists confirm that the Justinianic Plague was caused by the bacterium Yersinia pestis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
Breaking Biology Technology: